Hemoporfin-mediated photodynamic therapy for the treatment of port-wine stain: A multicenter, retrospective study

作者：Zhang, Xiaofeng; Yuan, Chen; Xiao, Xuemin; Yin, Rui; Lei, Hongzhao; Li, Yan; Zheng, Shumao; Wen, Sijian; Li, Dongsheng; Wang, Xuejun; Lu, Zhong; Zhang, Yunfeng; Zeng, Weihui; He, Sijin; Li, Yuzhen; Jian, Dan; Yang, Jun; Zhong, Hua; Han, Dawei; Chen, Xiaoying; Zhou, Junfeng; Cai, Yantao; Peng, Xi; Li, Zhiming; Liu, Xueying; Lin, Tong; Zhang, Ruzhi; Li, Guang; Zhuang, Yin; Liu, Ling; Yan, Yan^*; Wang, Baoxi^*

来源：Photodiagnosis and Photodynamic Therapy, 2023, 42: 103545.

DOI：10.1016/j.pdpdt.2023.103545

• Port-wine stain
• Hemoporfin-PDT
• Multicenter study
• Large-scale samples
• Efficacy
• Safety

Background: Hemoporfin-mediated photodynamic therapy (Hemoporfin-PDT) has been approved for port-wine stain (PWS) in China in 2017. This study evaluated the efficacy and safety of Hemoporfin-PDT for PWS in a real life setting and investigated factors that influence the efficacy.Methods: A multicenter retrospective study included patients with PWS who underwent Hemoporfin-PDT in 29 hospitals across China and completed at least two months of follow-up. The efficacy was evaluated based on patien photographs.Results: A total of 1679 patients were included. After the first and second sessions of Hemoporfin-PDT, 63.5 and 75.3% of patients responded, respectively. The response rate of purple-type PWS was significantly lower than that of pink-type PWS (OR: 0.71, 95% CI: 0.54-0.94, P < 0.05), and there was no significant difference between thick-and pink-type (OR: 0.72, 95% CI: 0.42-1.22, P > 0.05). The response rate of PWS on the limbs was significantly lower than that on the mid-face (OR: 0.35, 95% CI: 0.23-0.53, P < 0.0001), while no significant difference was observed between PWS on the peripheral part of the face, neck or other parts of the body and PWS on the mid-face (P > 0.05). The response rate was lower in male patients with an age > 3 years or <= 6 years (P < 0.05). Previous treatment history did not affect the efficacy (P > 0.05). Hemoporfin-PDT was well tolerated.Conclusion: Patients with PWS have a good response and good tolerance to Hemoporfin-PDT.

• 单位
  哈尔滨医科大学; 郑州大学; 中国人民解放军第四军医大学; 中国医学科学院北京协和医院; 1; 吉林大学; 同济大学; 复旦大学; 北京大学; 苏州大学; y; 南方医科大学; 西安交通大学; 山东大学; 上海交通大学; 华中科技大学